3246 results about "High Blood Pressures" patented technology

Devices, systems and methods are disclosed for the formation of an arteriovenous fistula. Embodiments include catheter apparatus including an ablation element for creating and / or modifying the fistula. The devices, systems and methods can be used to treat patients with one or more numerous ailments including chronic obstructive pulmonary disease, congestive heart failure, hypertension, hypotension, respiratory failure, pulmonary arterial hypertension, lung fibrosis and adult respiratory distress syndrome.

A radiosurgical method for treating cardiorenal disease of a patient, the method including directing radiosurgery radiation from outside the patient towards one or more target treatment regions encompassing sympathetic ganglia of the patient so as to inhibit the cardiorenal disease. In an exemplary embodiment, the method further includes acquiring three dimensional planning image data encompassing the first and second renal arteries, planning an ionizing radiation treatment of first and second target regions using the three dimensional planning image data so as to mitigate the hypertension, the first and second target regions encompassing neural tissue of or proximate to the first and second renal arteries, respectively, and remodeling the target regions by directing the planned radiation from outside the body toward the target regions.

A method of cufflessly and non-invasively measuring blood pressure in a wrist region of a patient in association with a communication device that relays the information being measured includes: detecting a magnitude difference between a plurality of pulse wave signals detected from a wrist of a user; detecting feature points from an electrocardiogram (ECG) and pulse wave signals detected from the user; extracting variables needed to calculate the highest blood pressure and the lowest blood pressure using the detected feature points; and calculating the highest blood pressure and the lowest blood pressure of the user by deducing a scatter diagram using the extracted variables.

The invention provides a method of treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.

The present invention is generally related to the discovery of the therapeutic benefit of administering gamma-tocopherol and gamma-tocopherol derivatives. More specifically, the use of gamma-tocopherol and racemic LLU-alpha, (S)-LLU-alpha, or gamma-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.

This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

Methods and devices for reducing ventricle filling volume are disclosed. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to reduce ventricle filling volume or even blood pressure. When the heart is stimulated in a consistent way to reduce blood pressure, the cardiovascular system may over time adapt to the stimulation and revert back to the higher blood pressure. In some embodiments, the stimulation pattern may be configured to be inconsistent such that the adaptation response of the heart is reduced or even prevented. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to cause at least a portion of an atrial contraction to occur while the atrioventricular valve is closed. Such an atrial contraction may deposit less blood into the corresponding ventricle than when the atrioventricular valve is opened throughout an atrial contraction.

The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing / treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.

Novel piperzine derivatives substituted on one nitrogen by an aromatic system and on the other nitrogen by (2,5-dioxopyrrolidin)-1-yl) alkanes or (2,6-dioxopiperidin-1-yl) alkanes have been found to exhibit selective alpha 1A adrenergic activity. The compounds are useful for treatment of disease conditions, such as peripheral vascular disease, congestive heart failure, hypertension and especially benign prostatic hypertrophy.

A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and / or heart failure. ARB includes S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.

This document provides devices and methods for the treatment of heart conditions, hypertension, and other medical disorders. For example, this document provides devices and methods for treating atrial fibrillation by performing thoracic vein ablation procedures, including pulmonary vein myocardium ablation. In some embodiments, the ablation is performed in coordination with the delivery a pharmacological agent that can abate the formation of tissue stenosis or neointimal hyperplasia caused by the ablation.

The invention discloses an imidazole-5-carboxylic acids derivative and the manufacturing method. It is the angiotensin II acceptor antagon. It has strong angiotensin II antagonize activity and high blood pressure proofing activity. And it could be used as therapeutic agent to cure high blood pressure.

The invention discloses Chinese medicated liquor for treating hypertension and a preparation method thereof. The Chinese medicated liquor is prepared from sun-dried ginseng, Radix Astragali, bighead atractylodes rhizome, Tuckahoe, tuber fleeceflower root, dried rhizome of rehmannia, white paeony root, angelica, bupleurum, dried orange peel, sealwort, centipedes, pilose antler, stir-baked semen ziziphi spinosae, thinleaf milkwort root-bark, Indian bread with hostwood, licorice, walnut, raisins, white spirit and other raw materials. Combining the raw materials, the Chinese medicated liquor takes both qi and blood into consideration, coordinates defensive qi and nutritive qi, makes qi and blood circulating in the whole body, coordinates the relationship between yin and yan, combines deintoxication and nourishing, removing blood stasis without hurting human body, maintains normal upbearing and downbearing of qi and blood, thereby reducing blood pressure.

Methods and devices for reducing ventricle filling volume are disclosed. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to reduce ventricle filling volume or even blood pressure. When the heart is stimulated in a consistent way to reduce blood pressure, the cardiovascular system may over time adapt to the stimulation and revert back to the higher blood pressure. In some embodiments, the stimulation pattern may be configured to be inconsistent such that the adaptation response of the heart is reduced or even prevented. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to cause at least a portion of an atrial contraction to occur while the atrioventricular valve is closed. Such an atrial contraction may deposit less blood into the corresponding ventricle than when the atrioventricular valve is opened throughout an atrial contraction.

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

The invention provides a sleep-improving and health-care drug pillow, relating to a health-care medical product, in particular to making materials and process of the sleep-improving and health-care drug pillow. A drug core of the pillow mainly comprises the following raw materials in parts by weight: 1000 parts of cottonseeds, 500 parts of buckwheat shell, 20 parts of tea, 30 parts of spina date seed, 30 parts of schisandra, 20 parts of lily, 20 parts of ganoderma lucidum, 30 parts of akebia stem, 30 parts of tuber fleeceflower root, 10 parts of cordyceps, 10 parts of Chinese angelica, 30 parts of rehmannia root, 10 parts of safflower, 30 parts of red-rooted salvia root, 10 parts of longan, 30 parts of common clubmoss herb, 30 parts of garden balsam stem, 10 parts of Chinese atractylode rhizome, 10 parts of clematis root, 30 parts of pawpaw, 30 parts of divaricate saposhnikovia root, 30 parts of dried orange peel, 20 parts of costustoot, 20 parts of polygala root, 30 parts of Szechwan lovage rhizome, 10 parts of honeysuckle, 20 parts of glossy privet fruit, 10 parts of wild chrysanthemum, 10 parts of lonicera chrysantha flower, 10 parts of amomum shell, 20 parts of mint, 30 parts of galanga, 20 parts of bergamot, 20 parts of coptis, 20 parts of amur corktree bark, 10 parts of tuber fleeceflower stem, 10 parts of dwarf lilytruf tuber, 10 parts of dandelion, 30 parts of radix astragali, 30 parts of nutgrass galingale rhizome, 2000 parts of millet mature vinegar, 30 parts of honey and 30 parts of yellow wine and is refined by adopting the processes of soaking, roasting, brewing, mixing and the like. The sleeping-improving and health-care pillow has the advantages of simple making process and strong drug efficacy and has special curative effects on long-term insomnia, high blood pressure, headache, tinnitus and cervical pain.

A multi-colored health care tofu containing fruit and vegetable comprises the following raw materials with the weight portions of 8 to 10 portions of soybean, 4 to 10 portions of fruits, 8 to 10 portions of vegetables and 0.3 to 1 portions of ecological coagulant, wherein, the fruit and the vegetable are the fruits and the vegetables with the pH of less than 7. The ecological coagulant is the mixture of glucose and plaster which is in the ratio of 1 to 3:22 to 28. The production process comprises screening and sorting soybean, soaking and removing peels, grinding for separation, mixing and coloring by adding the extracted natural vegetable juice and fruit juice, cooking and coagulating, squeezing and forming and packing the finished products. In the invention, algin, mannite, plant fiber, protein, a plurality of amino acids, a plurality of vitamins, a plurality of trace elements including calcium, iron and selenium which are the essential matter inside the body are added, which can effectively prevent a plurality of diseases including high blood pressure, obesity, cardiovascular genomic, biliary calculus and other diseases.

Compounds of the formulawherein R1, R2, R3, R4, X and Y are as defined, which have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis, and the like; allergic diseases such as asthma, or disorders of male or female genital function and the like.

The invention discloses an agent box, which is characterized by the following: utilizing the relation between mononucleotide polymorphism site E112D genetype of important enzyme praline carboxypeptidase gene on vessel or esoderma regulating access and ACEI medical effect; forecasting ACEI medical effect; possessing good ACEI medical effect when genetype as 112EE pure wild-type; possessing bad effect when the genetype as 112ED heterozygous type or 112DD pure saltant; incorporating polymorphism parting oligonucleotide of E112D polymorphism site genetype with praline carboxypeptidase gene to test biological sample and related agent. This invention improves effectiveness and safety of clinic medicine, which provides criterion for new medicine of high blood pressure.

The invention discloses a preparation method for highly effective compound dietary cellulose. The method of the invention is characterized in that: the highly effective compound dietary cellulose is prepared with the following materials, insoluble dietary fiber, water-soluble dietary fiber, vitamin C and lactic acid bacteria powder, in definite proportions. The product of the invention is the highly effective compound dietary cellulose which is provided with dual characteristics of insoluble dietary fiber and water-soluble dietary fiber and the dosage form of the product can be capsules or granules. The long-term taking of the product of the invention can ensure obvious curative effects on high blood pressure, high blood fat, high cholesterol, diabetes, obesity, constipation, gastro-intestinal diseases, etc. If being added with different materials such as microcrystalline celluloses, magnesium stearate, maltodextrin, citric acid, sodium bicarbonate and PEG6000, according to different preparation forms, the product can also be prepared into tablets, chewable tablets and effervescent tablets. The highly effective compound dietary cellulose of the invention has simple, scientific and reasonable prescription, simple technology and stable quality, and is easy to be produced in large scale, thus being a safe and green health-care food product.

Dependent variables believed to contribute to a likelihood of falling are analyzed using a latent class analysis. The dependent variables are biomedical factors, which may include, for example, arthritis, high blood pressure, diabetes, foot disorders, Parkinson's Disease, stroke, eye disorder, limb disorder, or proprioceptive disorder. Data pertaining to the biomedical factors is gathered from a population of individuals at risk of falling. Covariate data, including for example age and the number of prescriptions taken, is further analyzed against latent class data. For a particular group of at risk individuals, a set of five classes produced useful results broadly corresponding to groups representing individuals who have: good health; a range of diseases; Parkinson's Disease; arthritis; and high blood pressure. A probability of falling is determined, relative to the group of individuals with good health.

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

Food products fortified with a therapeutically effective amount of milk mineral are administered for the treatment of high blood pressure, stroke, obesity, kidney stones, colon cancer, breast cancer, head and neck tumors, premenstrual syndrome, postpartum depression, hypertensive disorders of pregnancy, Type-2 diabetes, depression, asthma, inflammatory bowel disease, attention deficit disorder, migraine headaches, kidney disease, hypercholesterolaemia, congestive heart failure, or immune deficiency.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

The invention relates to a hydroxysaffloryellow A extracted from Chinese medicinal material safflower, a relative preparation method and application thereof. The inventive extraction method of hydroxysaffloryellow A is stuffed into chromatography column according to different diameter-height ratios, the invention uses the upper sample to process column chromatography according to different ratios between upper sample volumes and bed volumes, to separate and purify safflower extract. The invention has simple process, few steps, low cost, high yield, no environment pollution and suitability for industrialized and large-scale production. The yield of extracted hydroxysaffloryellow A is higher than 50%, while the hydroxysaffloryellow A content tested by high-effect liquid hydroxysaffloryellow A reaches 99.5%. The drug prepared from the hydroxysaffloryellow A can effectively prevent and treat cerebrovascular diseases as cerebral infraction and hypertensive cerebral hemorrhage or the like.

Described are a number of compositions, namely a konjac mannan mixture, a ginseng composition, and a composition comprising konjac mannan and American ginseng. Methods of use of these compositions are described including their use for reducing blood glucose in non-diabetic and diabetic individuals, as well as reducing postprandial blood glucose in such individuals. Applications in the treatment of hyperlipidemia, high blood pressure, an increase in nitric oxide, Syndrome X and cardiovascular disease are also described. Various other applications of the compositions and methods are also described.

The invention discloses a health-care noodle with functions of lowering pressure, blood lipid and sugar and softening blood vessel. The health-care noodle comprises the following materials in parts by weight: 60-80 parts of flour, 4-8 parts of gynostemma pentaphyllum, 3-5 parts of gingko leaves, 2-4 parts of polygonum multiflorum, 3-4 parts of haw, 2-3 parts of chrysanthemum, 1-3 parts of medlar, 5-10 parts of black fungus, 5-10 parts of mushroom and 2-6 parts of onion. The product has excellent improvement effects for patients suffering from hypertension, hyperglycemia and hyperlipoidemia, persons with poor sleep and endocrinopathy and in fatigue state for a long time, heart cerebrovascular sufferers and sub-health persons and better preventive treatment effects for arteriosclerosis, hypertension and coronary heart disease and can enhance disease-resistant abilities. The invention increases new noodle variety and ensures that the traditional noodle is more nutritive without any side effect.

The invention relates to a traditional Chinese medicine for treating cardiac, cerebral and vascular diseases; the drug is composed of forty kinds of crude drugs by weight parts: milk veteh, salvia miltiorrhiza, root of common peony, ligusticum wallichii, lumbricus, sanguisuga, rhizoma acori graminei, polygala root, red ocher, oyster, angelica, the root of kudzu vine, arisaema cum bile and the like; the preparation method is that: (1) the crude drugs are prepared into water extract liquid; (2) the water extract liquid is prepared into oral liquid; (3)the water extract liquid obtained by the step (1) is dried, crushed, sieved, undersize material is extracted powder; (4) the extracted powder prepared by the step (3) is prepared into various dosage forms. The preparation method of crude powder is that: lime earth of the crude drugs is sieved, and then the crude drugs are crushed and sieved, the undersize material is taken out and is sterilized to be crude powder, and the crude powder is prepared into various dosage forms. The traditional Chinese medicine has the major functions of treating miocardial infarction and angina caused by coronary heart disease, high blood pressure and cerebral thrombosis, hemiplegia, cerebral infarction, cerebrovascular accident, sequel of apoplexy and other symptoms, and the medicine has obvious effect on headache, dizziness and heart cerebrovascular diseases caused by high blood pressure and cerebral circulation insufficiency.